2 assets in Ovarian Clear Cell Cystadenocarcinoma

Therapeutic assets addressing Ovarian Clear Cell Cystadenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Adavosertib Ovarian Clear Cell Cystadenocarcinoma	National Cancer Institute (NCI)	P2	CCC (52)
Sapanisertib Ovarian Clear Cell Cystadenocarcinoma	National Cancer Institute (NCI)	P1	CC (43)